Literature DB >> 15196550

Analysis of chromosomes 3, 7, X and the EGFR gene in uterine cervical cancer progression.

R Marzano1, G Corrado, R Merola, C Sbiroli, F Guadagni, E Vizza, F Del Nonno, M Carosi, M Galati M, I Sperduti, A M Cianciulli.   

Abstract

The aim of this study was to investigate the possible role of genetic alterations in the genesis and progression of cervical carcinomas. We analysed the 3, 7, X aneusomy of chromosomes and the status of the epidermal growth factor receptor (EGFR) gene by fluorescence in situ hybridisation (FISH) analysis. Polysomy of chromosomes 3 and X defined the transition from high-grade squamous intraepithelium lesions (HSIL) to cervical carcinoma. Chromosome 7 monosomy and polysomy did not show any statistical significant differences between the groups examined. When we compared the chromosomal aneusomies in all of the specimens using the Kruskal-Wallis test, significant differences (P = 0.0001, P = 0.0001 for chromosomes 3 and X, respectively) were observed. Using a ratio of the EGFR gene signals and chromosome 7 centromeric signals, no samples showed gene amplification. Our results demonstrate the importance of chromosomal 3 and X aneusomies in the development and progression from HSIL to cervical carcinoma, highlighting their usefulness as genetic markers for identifying SILs at high-risk of progression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15196550     DOI: 10.1016/j.ejca.2004.03.015

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  7 in total

1.  Automated analysis of fluorescent in situ hybridization (FISH) labeled genetic biomarkers in assisting cervical cancer diagnosis.

Authors:  Xingwei Wang; Bin Zheng; Roy R Zhang; Shibo Li; Xiaodong Chen; John J Mulvihill; Xianglan Lu; Hui Pang; Hong Liu
Journal:  Technol Cancer Res Treat       Date:  2010-06

2.  Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.

Authors:  Alessandro D Santin; Michael W Sill; D Scott McMeekin; Mario M Leitao; Jubilee Brown; Gregory P Sutton; Linda Van Le; Patricia Griffin; Cecelia H Boardman
Journal:  Gynecol Oncol       Date:  2011-09       Impact factor: 5.482

3.  EGFR protein expression and gene amplification in squamous intraepithelial lesions and squamous cell carcinomas of the cervix.

Authors:  Qing Li; Yongfeng Tang; Xue Cheng; Jie Ji; Jingmin Zhang; Xiaojun Zhou
Journal:  Int J Clin Exp Pathol       Date:  2014-01-15

4.  Clinical significance of hTERC gene amplification detection by FISH in the screening of cervical lesions.

Authors:  Yuan Zhang; Xiaobei Wang; Ling Ma; Zehua Wang; Lihua Hu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-06-10

5.  A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study.

Authors:  Russell J Schilder; Michael W Sill; Yi-Chun Lee; Robert Mannel
Journal:  Int J Gynecol Cancer       Date:  2009-07       Impact factor: 3.437

6.  A Comprehensive Review of Dysregulated miRNAs Involved in Cervical Cancer.

Authors:  Garima Sharma; Pradeep Dua; Subhash Mohan Agarwal
Journal:  Curr Genomics       Date:  2014-08       Impact factor: 2.236

7.  An Optimization-Driven Analysis Pipeline to Uncover Biomarkers and Signaling Paths: Cervix Cancer.

Authors:  Enery Lorenzo; Katia Camacho-Caceres; Alexander J Ropelewski; Juan Rosas; Michael Ortiz-Mojer; Lynn Perez-Marty; Juan Irizarry; Valerie Gonzalez; Jesús A Rodríguez; Mauricio Cabrera-Rios; Clara Isaza
Journal:  Microarrays (Basel)       Date:  2015-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.